For at opretholde den kliniske effekt bør MPA- eksponeringen overvåges, og CellCept- doserne justeres i forhold til dette, når rifampicin administreres samtidigt.
It is recommended to monitor MPA exposure levels and to adjust CellCept doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.